Aleniglipron Achieves Best-in-Class Oral GLP-1 Efficacy with Over 16% Weight Loss in Phase 2 Data—Low Discontinuation Rates Highlight Tolerability
Market Chameleon (Mon, 16-Mar 11:45 AM)
Aleniglipron Sets New Standard in Oral GLP-1 Weight Loss: Phase 2 Data Show Sustained Efficacy and Strong Safety
Market Chameleon (Mon, 16-Mar 7:30 AM)
